Diao Kevin, Sun Yanqing, Yoo Stella K, Yu Cheng, Ye Jason C, Trakul Nicholas, Jennelle Richard L, Kim Paul E, Zada Gabriel, Gruen John P, Chang Eric L
Harvard Medical School, Boston, Massachusetts.
Department of Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California.
Cancer. 2018 Jan 1;124(1):167-175. doi: 10.1002/cncr.30984. Epub 2017 Sep 13.
Stereotactic radiosurgery (SRS) alone is an increasingly accepted treatment for brain metastases, but it requires adherence to frequently scheduled follow-up neuroimaging because of the risk of distant brain metastasis. The effect of disparities in access to follow-up care on outcomes after SRS alone is unknown.
This retrospective study included 153 brain metastasis patients treated consecutively with SRS alone from 2010 through 2016 at an academic medical center and a safety-net hospital (SNH) located in Los Angeles, California. Outcomes included neurologic symptoms, hospitalization, steroid use and dependency, salvage SRS, salvage whole-brain radiotherapy, salvage neurosurgery, and overall survival.
Ninety-three of the 153 patients were private hospital (PH) patients, and 60 were SNH patients. The median follow-up time was 7.7 months. SNH patients received fewer follow-up neuroimaging studies (1.5 vs 3; P = .008). In a multivariate analysis, the SNH setting was a significant risk factor for salvage neurosurgery (hazard ratio [HR], 13.65; P < .001), neurologic symptoms (HR, 3.74; P = .002), and hospitalization due to brain metastases (HR, 6.25; P < .001). More clinical visits were protective against hospitalizations due to brain metastases (HR, 0.75; P = .002), whereas more neuroimaging studies were protective against death (HR, 0.65; P < .001).
SNH patients with brain metastases treated with SRS alone had fewer follow-up neuroimaging studies and were at higher risk for neurologic symptoms, hospitalization for brain metastases, and salvage neurosurgery in comparison with PH patients. Clinicians should consider the practice setting and patient access to follow-up care when they are deciding on the optimal strategy for the treatment of brain metastases. Cancer 2018;124:167-75. © 2017 American Cancer Society.
立体定向放射外科(SRS)单独治疗脑转移瘤越来越被广泛接受,但由于存在远处脑转移的风险,需要定期进行随访神经影像学检查。单独使用SRS治疗后,随访治疗机会的差异对治疗结果的影响尚不清楚。
这项回顾性研究纳入了2010年至2016年期间在加利福尼亚州洛杉矶的一家学术医疗中心和一家安全网医院(SNH)连续接受单独SRS治疗的153例脑转移瘤患者。观察指标包括神经系统症状、住院情况、类固醇使用及依赖情况、挽救性SRS、挽救性全脑放疗、挽救性神经外科手术以及总生存期。
153例患者中,93例为私立医院(PH)患者,60例为SNH患者。中位随访时间为7.7个月。SNH患者接受的随访神经影像学检查较少(1.5次对3次;P = 0.008)。在多变量分析中,SNH环境是挽救性神经外科手术(风险比[HR],13.65;P < 0.001)、神经系统症状(HR,3.74;P = 0.002)以及因脑转移瘤住院(HR,6.25;P < 0.001)的显著风险因素。更多的临床就诊对预防因脑转移瘤住院有保护作用(HR,0.75;P = 0.002),而更多的神经影像学检查对预防死亡有保护作用(HR,0.65;P < 0.001)。
与PH患者相比,单独接受SRS治疗的SNH脑转移瘤患者接受的随访神经影像学检查较少,出现神经系统症状、因脑转移瘤住院以及接受挽救性神经外科手术的风险更高。临床医生在决定脑转移瘤的最佳治疗策略时,应考虑医疗机构环境和患者获得随访治疗的机会。《癌症》2018年;124:167 - 175。© 2017美国癌症协会